NCT02156791View on ClinicalTrials.gov

Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM

PHASE2CompletedINTERVENTIONAL

Enrollment

61

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Hay Fever

Interventions

BIOLOGICAL

gpASIT+TM

Trial Locations (1)

01307

Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany, Dresden

Sponsors

Lead Sponsor

BioTech Tools S.A.

All Listed Sponsors

lead

BioTech Tools S.A.

INDUSTRY

NCT02156791 - Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM | Biotech Hunter | Biotech Hunter